Edition:
United States

Vericel Corp (VCEL.OQ)

VCEL.OQ on NASDAQ Stock Exchange Capital Market

4.72USD
8 Dec 2017
Change (% chg)

$-0.17 (-3.57%)
Prev Close
$4.90
Open
$4.90
Day's High
$5.00
Day's Low
$4.68
Volume
60,854
Avg. Vol
99,390
52-wk High
$6.30
52-wk Low
$2.25

Latest Key Developments (Source: Significant Developments)

Vericel Enters Into Expanded $25 Million Debt Facilities With Silicon Valley Bank And Midcap Financial
Thursday, 7 Dec 2017 08:00am EST 

Dec 7 (Reuters) - Vericel Corp ::VERICEL ENTERS INTO EXPANDED $25 MILLION DEBT FACILITIES WITH SILICON VALLEY BANK AND MIDCAP FINANCIAL TO SUPPORT ACCELERATING MACI UPTAKE AND INCREASED EPICEL USAGE.VERICEL-ENTERED INTO EXPANDED $15 MILLION TERM LOAN, RETAINED EXISTING $10 MILLION REVOLVING LINE OF CREDIT WITH SILICON VALLEY BANK,MIDCAP FINANCIAL SERVICES​.  Full Article

Vericel reports Q3 loss per share $0.16
Tuesday, 7 Nov 2017 07:00am EST 

Nov 7 (Reuters) - Vericel Corp :Vericel reports third-quarter 2017 financial results.Q3 loss per share $0.16.Q3 revenue $14.3 million versus I/B/E/S view $13.9 million.Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.Vericel Corp - ‍As of September 30, 2017, company had $15.5 million in cash compared to $23.0 million in cash at December 31, 2016​.  Full Article

Vericel Q2 loss per share $0.07
Wednesday, 9 Aug 2017 07:00am EDT 

Aug 9 (Reuters) - Vericel Corp ::Vericel reports second-quarter 2017 financial results.Q2 loss per share $0.07.Q2 revenue rose 32 percent to $17 million.Q2 revenue view $12.9 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.  Full Article

Vericel Corp enters distribution agreement with Orsini Pharmaceutical Services
Friday, 19 May 2017 04:13pm EDT 

May 19 (Reuters) - Vericel Corp :Co entered distribution agreement with Orsini Pharmaceutical Services Inc to appoint Orsini as specialty pharmacy distributor of Carticel.Initial term of distribution deal shall end on May 15, 2019, parties may renew distribution agreement for two additional two-year terms.  Full Article

Vericel Q1 loss per share $0.31
Wednesday, 10 May 2017 07:00am EDT 

May 10 (Reuters) - Vericel Corp :Vericel reports first-quarter 2017 financial results.Q1 loss per share $0.31.Q1 revenue $9.4 million.Q1 earnings per share view $-0.14 -- Thomson Reuters I/B/E/S.Q1 revenue view $14.4 million -- Thomson Reuters I/B/E/S.  Full Article

Vericel enters into license agreement with Innovative Cellular Therapeutics
Wednesday, 10 May 2017 07:00am EDT 

May 10 (Reuters) - Vericel Corp :Vericel Corp - entered into a license agreement with Innovative Cellular Therapeutics for development, manufacturing and commercialization of Vericel product portfolio.VERICEL - ICT will acquire exclusive rights to develop and distribute carticel, maci, ixmyelocel-t, and epicel in Greater China, South Korea, Singapore, and other countries in region.Says under terms of license agreement, Vericel will receive an upfront payment of $6.0 million.Says in addition, Vericel is eligible to receive about $8.0 million in development and commercial milestones.  Full Article

Vericel Q4 loss per share $0.34
Friday, 10 Mar 2017 07:15am EST 

Vericel Corp : Vericel reports fourth-quarter and year-end 2016 financial results . Q4 revenue $16.5 million versus i/b/e/s view $16.1 million . Q4 loss per share $0.34 . Q4 adjusted non-gaap loss per share $0.14 .Vericel - as of dec 31, 2016, co had $23.0 million in cash and cash equivalents compared to $14.6 million in cash and cash equivalents at december 31, 2015.  Full Article

Vericel receives FDA fast track designation for ixmyelocel-T
Tuesday, 21 Feb 2017 07:30am EST 

Vericel Corp :Vericel receives FDA fast track designation for ixmyelocel-T, an investigational product for the treatment of patients with advanced heart failure due to ischemic dilated cardiomyopathy.  Full Article

Vericel announces first MACI implant in U.S.to treat symptomatic cartilage defects of knee
Wednesday, 1 Feb 2017 07:00am EST 

Vericel Corp :Vericel announces first MACI implant in United States for treatment of symptomatic cartilage defects of knee.  Full Article

FDA approves MACI for treatment of symptomatic cartilage defects of knee in adults
Wednesday, 14 Dec 2016 07:10am EST 

Vericel Corp:FDA approves MACI for the treatment of symptomatic cartilage defects of the knee in adults.  Full Article

BRIEF-Vericel Enters Into Expanded $25 Million Debt Facilities With Silicon Valley Bank And Midcap Financial

* VERICEL ENTERS INTO EXPANDED $25 MILLION DEBT FACILITIES WITH SILICON VALLEY BANK AND MIDCAP FINANCIAL TO SUPPORT ACCELERATING MACI UPTAKE AND INCREASED EPICEL USAGE